SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is trending as investors debate the significance of recent earnings, marked by strong revenue growth but impacted by a distributor termination fee that will be reimbursed by Pepsi. The community is split, with some viewing the dip as a buying opportunity due to solid fundamentals and long-term growth potential, while others express concern over short-term noise and operational expenses. Discussions also revolve around market share, the Pepsi partnership, and analyst expectations following the earnings call.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending amid a bidding war for obesity assets, with Novo Nordisk and Pfizer vying for Metsera, driving speculation that Viking could be next. Community members suggest that Viking's pipeline may be undervalued compared to Metsera, while also actively discussing a potential buyout and Phase 3 trial data.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

ENVX is trending as investors discuss the potential impact of a delayed commercialization timeline due to required battery chemistry adjustments, sparking debates about management credibility and future revenue. Despite the setback, community members express optimism about a potential product reveal at CES and a committed phone OEM partnership, while others are losing faith and selling their shares. Broader discussions involve speculation about target price, patience for disruptive tech, supply chain diversification and overall market conditions.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending due to mixed reactions to a potential deal with the Trump administration to lower weight loss drug prices, with community members debating the long-term impact on revenue and market share amid increasing competition. The stock is also affected by news of a bidding war with Pfizer for Metsera and recent earnings, with discussions focusing on the company's strategy and future prospects. Discussions also center around reactions to an executive collapsing at a press conference.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is trending downwards following a weak outlook and lowered full-year guidance, sparking concerns of overvaluation among investors. The community is discussing risk management strategies like employing stop losses, with some expressing shock at the stock's sharp decline. Despite positive growth metrics, analysts' price targets are being questioned amidst the stock's significant drop.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions around its financial performance and broader political implications. The community is focused on potential market manipulation, the stock's valuation, and its ties to political events. Ongoing debates encompass government shutdowns and their economic effects.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo ($DUOL) is trending as the community debates its future following a significant drop despite reporting strong earnings, with analysts pointing to weaker-than-expected Q4 bookings. Discussions center on the potential impact of AI on language learning apps and whether Duolingo can maintain its competitive edge. Some traders are eyeing a potential rebound, while others remain skeptical about the company's long-term prospects and valuation.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The "crow with knife" meme coin, $CAW, is gaining attention for its multichain functionality and deflationary tokenomics, built with LayerZero protocol. Community members are excited about its presence on multiple chains like Solana, BSC, and Ethereum, and the absence of team wallets. The community emphasizes its organic growth and strong partnerships, suggesting potential for significant gains.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly ($LLY) is trending amid discussions about its strong position in the weight loss drug market, particularly against Novo Nordisk ($NVO), with many anticipating a positive earnings report. Community members are weighing the potential impact of upcoming announcements and comparing $LLY's prospects against competitors, including potential acquisitions. Traders are actively discussing technical indicators, potential price movements, and strategies involving options, highlighting both bullish and bearish perspectives.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending following an earnings report that beat expectations, with revenue growth attributed to strong customer acquisition and increased demand related to AI and cloud adoption; the community is discussing analyst upgrades and the potential for new highs, with some highlighting the stock's relative strength in the software sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Spotlight on Viking Therapeutics: Analyzing the Surge in Options Activity

<ul class="summary-bullets"><li>Eli Lilly led a Stocktwits poll, with 32% support, ahead of Novo Nordisk, Hims &amp; Hers Health and Viking Therapeutics at 16%.</li><li>Lilly and Novo advanced oral obesity drugs while nearing TrumpRx pricing deals to expand Medicare access for Zepbound and Wegovy.</li><li>Hims &amp; Hers pursued GLP-1 partnerships, and Viking gained attention for its dual GLP-1/GIP drug VK2735, described by Jefferies as “class-leading.”</li></ul>Eli Lilly topped a Stocktwits poll asking retail traders which obesity-drug stock they are most bullish on over the next five years, outpacing rival Novo Nordisk as investors weigh fresh policy developments and the next wave of obesity treatments.The survey of about 3,300 participants showed 32% of votes in favour of Eli Lilly, followed by Novo Nordisk and Hims &amp; Hers Health, tied at 26%, and Viking Therapeutics at 16%. The results come as the world’s biggest drugmakers prepare to expand access to their obesity therapies under an expected U.S. pricing plan, while smaller firms position for partnerships and new launches.<h2 class="st-heading-2">Lilly Leads With New Therapies And Policy Tailwinds</h2>Eli Lilly remains the frontrunner in the fast-growing obesity-drug market, driven by strong demand for its injectable therapies Zepbound and Mounjaro, both of which are based on the active ingredient tirzepatide. Zepbound is approved for adults with obesity or overweight and associated conditions.Eli Lilly’s Mounjaro and Zepbound sales beat market expectations in the third quarter (Q3), raking in over $10 billion combined, while Novo Nordisk’s Wegovy came in below estimates and Ozempic slightly exceeded forecasts&nbsp;(both generating close to $8 billion in sales),&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/10/30/eli-lilly-lly-earnings-q3-2025.html#:~:text=Mounjaro%20raked%20in%20%246.52%20billion,revenue%20for%20the%20third%20quarter.">CNBC</a>&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/11/05/wegovy-ozempic-maker-novo-nordisk-q3-earnings.html">reported</a>.The company has also completed Phase 3 trials for Orforglipron, a once-daily oral GLP-1 treatment that Lilly said met key regulatory criteria for a priority review submission this quarter. UBS analysts said the oral pill could widen Lilly’s reach in markets where injectable therapies face storage or cost barriers.In parallel, Lilly and Novo Nordisk are in talks with the U.S. administration under the “TrumpRx” initiative to lower the price of obesity drugs to about $149 per month in exchange for expanded Medicare coverage. The plan would represent the third major pricing agreement between the government and large pharmaceutical firms since September.<h2 class="st-heading-2">Novo Nordisk Ramps Up Obesity Pipeline Amid Profit Pressure</h2>Novo Nordisk, the maker of Wegovy and Ozempic, continues to expand its obesity-drug franchise but faces slowing sales growth and pricing challenges. The company lowered its full-year profit and sales forecasts, citing intensifying competition and weaker momentum in GLP-1 revenue.At the ObesityWeek 2025 conference, Novo presented late-stage data for its oral semaglutide 25 mg formulation, demonstrating significant weight loss and cardiovascular benefits comparable to those of its injectable product, Wegovy.&nbsp;Novo and Lilly are also in advanced discussions with the U.S. government to include their drugs in the TrumpRx pricing plan. Under the proposal, both companies would offer entry-level doses of Wegovy and Zepbound at about $149 per month for Medicare patients, potentially broadening access but reducing global pricing leverage.<h2 class="st-heading-2">Hims &amp; Hers Expands Access Model With GLP-1 Partnerships</h2>Digital health company Hims &amp; Hers Health has quickly become one of the most-watched newcomers in the obesity drug sector. The company, which offers telehealth-based access to GLP-1 weight-loss medications, said it is in discussions with Novo Nordisk to distribute Wegovy injections and an eventual oral version through its platform once regulatory approval is secured.Hims &amp; Hers expects to generate about $725 million in annual revenue from its weight-loss business in 2026, supported by new fulfillment and compounding facilities to meet growing demand. The firm’s total subscriber base has risen to nearly 2.5 million, and it continues to expand its range of prescription offerings tied to metabolic and wellness care.<h2 class="st-heading-2">Viking Therapeutics Advances Dual-Action Obesity Drug</h2>Viking is advancing VK2735, a dual GLP-1/GIP agonist being developed in both injectable and oral forms. The company recently began a maintenance dosing trial under its Vanquish program, evaluating weekly and monthly regimens in adults with obesity.Phase 2 results showed weight loss of up to 15%, with Jefferies describing the data as “class-leading” in the oral drug category. Viking said it plans to meet with the U.S. Food and Drug Administration later this year to discuss late-stage trial design and expects to file a new drug application for its next obesity candidate targeting the amylin receptor in 2026.<h2 class="st-heading-2">Stocktwits Traders Stay Bullish On GLP-1 Leaders</h2>On Stocktwits, retail sentiment was ‘extremely bullish’ for Eli Lilly, Novo Nordisk, and Hims &amp; Hers Health amid ‘high’ to ‘extremely high’ message volume, while sentiment for Viking Therapeutics was ‘bullish’ amid ‘high’ message volume.So far this year, Eli Lilly is up 21%, Hims &amp; Hers Health has gained 81%, while Novo Nordisk is down 43% and Viking Therapeutics has slipped 9%.A Stocktwits user said Viking’s new VK-2735 data showed rapid, dose-dependent weight loss and metabolic improvements, suggesting the dual GLP-1/GIP drug could avoid the nausea issues seen with Lilly and Novo. The user called it a “tolerability unlock” and said the upcoming Vanquish-1 trial could set up a true head-to-head test with market leaders.<stembedurl>https://stocktwits.com/LastResort/message/635054466</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The entrance to the Eli Lilly factory in Kinsale, Co Cork, where weight loss drug Mounjaro is made. Picture date: Sunday May 18, 2025.

Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years?

Eli Lilly led a Stocktwits poll, with 32% support, ahead of Novo Nordisk, Hims & Hers Health and Viking Therapeutics at 16%.

Equity

Lightning Round: I lack a catalyst to recommend Zoom, says Jim Cramer

'Mad Money' host Jim Cramer weighs in on stocks including: Viking Therapeutics, Altria, Zoom, and ProFrac Holdings...

Viking Therapeutics to Participate at Upcoming Investor Conferences

Viking Therapeutics to Participate at Upcoming Investor Conferences Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire SAN DIEGO, Nov. 4, 2025 SAN DIEGO, Nov. 4, 2025...

Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?

NVO faces slowing Wegovy and Ozempic momentum, pricing risks and fierce competition ahead of Q3 earnings.

<ul class="summary-bullets"><li>VKTX shares&nbsp;have surged&nbsp;about 45% in October,&nbsp;set for their strongest monthly gain of 2025.</li><li>Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.</li><li>Pfizer’s stalled Metsera deal and past struggles with its own obesity program added to speculation that Viking could become a future acquisition target.</li></ul>Viking Therapeutics shares have climbed nearly 45%&nbsp;in October, putting the stock on track for its best monthly performance of 2025, as investor excitement builds over its experimental obesity treatment and renewed analyst optimism.<h2 class="st-heading-2">Canaccord Starts Coverage With ‘Buy’&nbsp;</h2>Viking&nbsp;shares have rallied&nbsp;amid a slew of bullish analyst calls on Wall Street following quarterly earnings, with&nbsp;the latest coming from Canaccord Genuity’s initiation on Wednesday with a ‘Buy’ rating and $106 price target, representing an upside of 178% from the stock’s last close. The brokerage firm said Viking stands out as a leader in the obesity drug development space, citing its strong Phase 2 efficacy data from August for the oral version of VK2735.Canaccord expects readouts from Viking’s two Phase 3 trials in 2027 and mid-2028, and believes VK2735 can differentiate on multiple fronts in a crowded obesity drug pipeline.<h2 class="st-heading-2">Pfizer And Novo Nordisk Fuel M&amp;A Speculation</h2><a href="https://stocktwits.com/news-articles/markets/equity/retail-investors-expect-viking-therapeutics-to-bag-deal/cLGFym0R3xj">Investor chatter also intensified</a> after Novo Nordisk submitted an unsolicited proposal to acquire Metsera, a company that Pfizer had already agreed to purchase in September.Metsera has given Pfizer four business days to adjust its offer, fueling speculation among traders on Stocktwits that Pfizer might turn its attention to Viking if its Metsera deal falls through. Pfizer discontinued its own oral weight-loss candidate, Danuglipron, in April 2025, following safety issues, and has been seeking other ways to re-enter the obesity market.<h2 class="st-heading-2">Viking’s Obesity Drug Program</h2>Viking is developing VK2735, a dual agonist of the GLP-1 and GIP receptors, both of which play key roles in regulating glucose, appetite, and body weight. The company is testing subcutaneous and oral versions of the therapy in clinical trials.Early-stage data have shown positive safety and efficacy signals, reinforcing Wall Street’s belief that Viking could become a meaningful player in the weight-loss drug race dominated by Novo Nordisk and Eli Lilly.<h2 class="st-heading-2">Q3 Earnings And Outlook</h2>Viking Therapeutics reported a net loss of $52.3 million for the third quarter, in line with expectations, as it continues to invest heavily in its obesity and metabolic disease pipeline. Viking said it plans to meet with the U.S. Food and Drug Administration (FDA) by year-end to discuss advancing the oral formulation into late-stage clinical trials.The company noted that Phase III enrollment for its injectable version of VK2735 remains ahead of schedule, with completion expected in early 2026. A maintenance dosing study is currently underway to assess how best to sustain weight loss over time.&nbsp;Viking also plans to file an Investigational New Drug (IND) application with the FDA in the first quarter of 2026 for its next program targeting the amylin receptor, a mechanism that could complement GLP-1 and GIP therapies by improving appetite control and weight regulation.<h2 class="st-heading-2">Stocktwits Users See Viking At Center Of Pfizer–Novo Rivalry&nbsp;</h2>On Stocktwits, retail sentiment for Viking was ‘extremely bullish’ amid a 200% jump in 24-hour message volume.<figure class="image"><img style="aspect-ratio:969/139;" src="https://news.stocktwits-cdn.com/vktx_ss_jpg_85eeea1fb9.webp" alt="vktx ss.jpg" width="969" height="139"><figcaption>VKTX sentiment and message volume as of October 31 | Source: Stocktwits</figcaption></figure>Some traders speculated that Novo Nordisk’s renewed bid for Metsera may be tied to competitive pressure from Viking’s obesity program. One bullish user&nbsp;<a href="https://stocktwits.com/biolover/message/634429740">suggested</a> Novo’s main interest in Metsera is its early-stage oral GLP-1/GIP agonist, adding that Novo knows Viking’s oral 2735 could be a long-term threat.<stembedurl>https://stocktwits.com/biolover/message/634429740</stembedurl>Another trader&nbsp;<a href="https://stocktwits.com/Bagholding_VKTX/message/634425707">agreed</a>,&nbsp;speculating Novo may have approached Viking before turning to Metsera, but “panicked” once Pfizer entered the picture. The user added that institutional investors may share the same view, noting Viking’s strong price reaction.<stembedurl>https://stocktwits.com/Bagholding_VKTX/message/634425707</stembedurl><a href="https://stocktwits.com/symbol/VKTX">Viking’s stock</a> has declined 5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise

Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.

<ul class="summary-bullets"><li>Novo Nordisk announced on Thursday that it has submitted an unsolicited proposal to acquire Metsera, following Pfizer's agreement to acquire the smaller obesity biopharmaceutical company in September.</li><li>Pfizer was previously developing its own oral weight-loss drug, Danuglipron, but discontinued its development in April 2025 due to liver enzyme elevations in patients.</li><li>The company is now looking to enter the booming obesity market with an acquisition. &nbsp;</li></ul>Retail investors on Stocktwits expect Pfizer to make an acquisition bid for Metsera’s rival, Viking Therapeutics, as the company’s agreed-upon deal with Metsera hangs in limbo.Danish drugmaker Novo Nordisk (NVO) <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-submits-revised-bid-for-metsera-enters-bidding-war-with-pfizer/cLGFsgdR3x2">announced</a> on Thursday that it has submitted an unsolicited proposal to acquire Metsera, Inc. (MTSR), following Pfizer's (PFE) agreement to acquire the smaller obesity biopharmaceutical company in September. Metsera has now given Pfizer four business days to negotiate potential adjustments to the existing transaction. The company also noted it would be entitled to terminate the Pfizer merger agreement if Novo’s proposal continues to constitute a superior proposal.&nbsp;“The best part would be if PFE lets NVO walk away with MTSR rather than up its own bid a few billion dollars, and instead makes a better offer to VKTX,” a Stocktwits user wrote.<stembedurl>https://stocktwits.com/spodero/message/634314721</stembedurl>Another sees Viking ending up with a good deal in time.<stembedurl>https://stocktwits.com/Idvst8/message/634311871</stembedurl>Shares of VKTX traded 10% higher at the time of writing. On Stocktwits, retail sentiment around VKTX stayed within the ‘bullish’ territory while message volume remained at ‘high’ levels.Pfizer was previously developing its own oral weight-loss drug, Danuglipron, but discontinued its development in April 2025 due to liver enzyme elevations in patients. The company is now looking to enter the booming obesity market with an acquisition.<h2 class="st-heading-2">Viking’s Obesity Program</h2>Viking, meanwhile, is evaluating both subcutaneous and oral formulations of its obesity program VK2735 in clinical trials. It is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Activation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both.In early and mid-stage trials, subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> is down 4% this year and approximately 46% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-recalls-cybertrucks-for-second-time-in-october-this-time-for-faulty-light-bar/cLGFud9R3xe">Tesla Recalls Cybertrucks For Second Time In October – This Time For A Faulty Light Bar</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera 

Viking and Metsera are both attempting to develop drugs for the treatment of obesity.

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek 2025

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek 2025 Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in...

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil

VKTX posts a wider Q3 loss and no sales, as R&D costs surge and obesity drug studies drive spending higher.

$LLY

$NVO

$VKTX

$HIMS

Which obesity-drug stock are you most bullish on over the next 5 years?

VKTX
Viking Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VKTX News

VKTXViking Therapeutics Inc